SIGLEC‑15: how some tumors hide from the immune system
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
This research tests whether blocking SIGLEC‑15 can help the immune system attack cancers that do not respond to PD‑1/PD‑L1 therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11231678 on NIH RePORTER |
What this research studies
The researchers used a genome‑scale screen of human membrane proteins and discovered SIGLEC‑15 as a molecule that suppresses T cell activity in tumors. They are studying where SIGLEC‑15 is expressed in human cancers and how it differs from PD‑L1, including its presence on tumor cells and tumor‑associated macrophages. The team tests monoclonal antibodies that block SIGLEC‑15 in human cancer cell systems and in mouse tumor models to see if T cell responses and tumor control improve. The long‑term aim is to develop a new immunotherapy option for patients whose tumors are PD‑L1 negative or who do not benefit from current checkpoint drugs.
Who could benefit from this research
Good fit: Ideal candidates would be people with cancers that show SIGLEC‑15 expression or whose tumors have not responded to PD‑1/PD‑L1 immunotherapy.
Not a fit: Patients whose tumors lack SIGLEC‑15 expression or who are not eligible for experimental antibody trials are less likely to benefit.
Why it matters
Potential benefit: If successful, this work could lead to a new immune‑based treatment for cancers that fail to respond to current PD‑1/PD‑L1 therapies.
How similar studies have performed: Early laboratory and mouse model studies showed promising results with SIGLEC‑15 blockade, but effectiveness in people has not yet been proven.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wang, Jun — New York University School of Medicine
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.